- Home
- IHRT vs RIGL Comparison
IHRT vs RIGL Comparison
Compare IHRT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IHRT | RIGL |
|---|---|---|
| Founded | 1974 | 1996 |
| Country | United States | United States |
| Employees | 9550 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.5M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | IHRT | RIGL |
|---|---|---|
| Price | $3.55 | $36.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.25 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 725.4K | 353.9K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $9.96 | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $83.68 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $1.54 | $19.51 |
| 52 Week High | $6.56 | $52.24 |
Technical Indicators
Market Signals| Indicator | IHRT | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 42.92 |
| Support Level | $3.61 | $33.39 |
| Resistance Level | $3.73 | $36.95 |
| Average True Range (ATR) | 0.21 | 1.88 |
| MACD | -0.03 | -0.91 |
| Stochastic Oscillator | 25.07 | 18.52 |
Price Performance
Historical ComparisonAbout IHRT iHeartMedia Inc.
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.